International Journal of Radiation Oncology, Biology, Physics 1998: Vol 42 Index

9 Pages·1998·1.8 MB·English

Int. J.R adiation Oncology Biol. Phys., Vol. 41, No. 4, pp. 1199-1202, 1998
Copyright © 1998 Elsevier Science Inc
Printed in the USA. All rights reserved
PII S0360-3016(98)00000-0
AUTHOR INDEX
Abrams, R. A., 59 Bishop, K., 807 Chou, S.-C., 727 Ding, I., 885
Acimovic, L., 161 Black, P. McL., 573 Christianson, T. J. H., 921 Dobrowsky, E., 803
Adamietz, I. A., 959 Blasko, J. C., 1063 Christodoulou, D., 795 Dobrowsky, W., 803
Agarwala, S., 581 Bloching, M., 35 Clark, J., 345 Donaldson, S. S., 125
Agboola, O., 155 Bloomer, W. D., 775 Clifford, S., 1063 Dorszewski, A., 617
Ahles, T. A., 1105 Boissel, P., 935 Cloutier, D. A., 1097 Douglass, H. O., Jr., 269
Ahrens, S., 379 Boisserie, G., 179 Coad, T., 277 Downes, S., 385
Ahrnes, S., 1001 Bolek, T. W., 147 Coche-Dequeant, B., 237 Dray, M., 21
Akine, Y., 989 Bolla, M., 487 Coffin, D., 839 Driever, P. H., 959
Akiyama, N., 913 Bonnaud, G., 21 Cohen, A. M., 51, 325 Drzymala, R. E., 1, 1163
Alberto, P., 487 Bonner, J. A., 921 Cohen, B. H., 981 Dunst, J., 35, 379, 1001
Aleksandrovic, J., 161 Bosch, W. R., 213 Coia, L. R., 43, 1069 Durand, R. E., 711
Alexander, E., Ill, 573 Bottcher, H. D., 959 Colas-Linhart, N., 179 Durdux, C., 21
Amdur, R. J., 1105 Bourdin, S., 237 Coleman, C. N., 507, 781 Duval, P., 1033
Amer, M. H., 91 Bova, F. J., 591 Collingridge, D. R., 731
Ames, M. M., 969 Boxwala, A. A., 455 Collins, J. M., 289
Anderson, B., 1049 Brady, L., 361 Comack, R., 507 Edwards, B., 731
Anderson, L., 325 Brady, L. W., 1177 Connelly, P., 1015 Ehrnrooth, E., 895
Anderson, R. F., 827 Brambilla, C., 487 Conroy, T., 935 Eisenberg, B. L., 43
Andrejevic-Blant, S., 403 Brauers, G., 731 Constantinescu, A., 747 Elliott, P., 1033
Anscher, M. S., 73 Braun, R. D., 723, 855 Constine, L. S., 885 Ellis, T. L., 591
Antell, A., 495 Braylan, R. C., 147 Cook, J. A., 795 El-Mohri, Y., 437
Antich, P. P., 747 Breidahl, T., 891 Cooke, A. L., 117 El-Senoussi, M., 91
Antoine, J. E., 299 Breithardt, G., 617 Cooper, H. S., 43 Emami, B., 263, 469
Antolak, J. A., 661 Brem, H., 631 Cooper, J. S., 1069 Engel, C. J., 319
Antonuk, L. E., 437 Bright, S. J., 817 Corn, B. W., 101, 501 Engelhardt, E. L., 741
Arcangeli, G., 1119, 1119 Brown, S. L., 789 Cottrill, C. P., 807 Engelholm, S. A., 1041
Arnold, S. M., 607 Buatti, J. M., 147, 591 Courdi, A., 237 Enker, W. E., 325
Arthur, D. W., 1178 Buchsbaum, D. J., 817 Cowan, D. S. M., 905 Eriksson, T. B., 1147
Asbell, S. O., 263 Buckner, J. C., 969 Cox, J. D., 479 Esche, B., 155
Atkinson, K., 1033 Buller, R. E., 1049 Cross, P., 155 Essig, M., 995
Averette, H. E., 1015 Bundy, B. N., 1015 Cummings, B. J., 331 Etienne, M.-C., 237
Ayene, I. S., 769 Burke, M. D., 763 Curiel, D. T., 817 Eulert, J., 397
Bush, D. A., 299 Evans, S. M., 871
Byhardt, R., 263
Bagniewki, P. J., 969 Da Silva, V., 155
Byhardt, R. W., 469
Baillet, F., 179 D’ Agostino, R. B., Jr. Fang, F.-M., 541
Bakri, Y., 91 Dagovic, A., 1091 Feelisch, M., 795
Balch, C. S., 289 Campion, J.-P., 29 Dalrymple, C., 1033 Feig, B. W., 563
Ballinger, J. R., 737 Cance, W., 345 D’ Amico, A. V., 507 Fernandez-Checa,
Ballo, M. T., 1007 Candeias, L. P., 917 D’ Angelo, L., 1119 Fessi, H., 179
Banks, D. A., 223 Cantor, A., 257 Dar, A. R., 313 Finkelstein, J. N.,
Barker, B. R., 747 Cao, L., 909 Dardoufas, K., 551 Firth, L., 1033
Barnett, G. H., 981 Caral, L., 977 Das, I. J., 11 Fisher, B., 469
Bartelink, H., 247, 525 Cardinale, R. M., 431 Dassonville, O., 237 Fisher, B. J., 117,
Barthel, T., 397 Carter, J., 1033 Dagu, A., 705 Fisher, C., 811
Battista, J., 277 Cascino, T. L., 969 Dawson, L. A., 1155 Fisher, S. G., 557
Bauer, C., 1085 Casey, L., 257 Dayal, Y., 269 Fleming, Y., 641
Bauman, G. S., 313, 319 Cellini, N., 65 D’Costa, L., 1033 Flentje, M., 397
Becker, A., 35 Chance, B., 871 De Jaeger, K., 717 Flickinger, J. C., 581
Bedford, J. L., 673 Chaney, E. L., 455 De Nijs, R., 525 Folkes, L. K., 917
Benedict, S. H., 431 Chao, C., 335 Dearnaley, D. P., 673 Fontolliet, C., 403
Benoit, B., 155 Chao, K. S. C., 681 Debus, J., 995 Fossella, F. V., 479
Bensadoun, R.-J., 237 Chao, K. S. Clifford, 1077 DeGraff, W., 795 Fowble, B., 11, 105
Bentel, G., | Chaplin, D. J., 731, 849 del Charco, J. O., 147 Fowler, A., 1033
Bentel, G. C., 73 Chapman, J. D., 741 Delaney, T. F., 611 Fraass, B. A., 137, 651
Bergstrom, P., 305 Chapman, W. B., 331 Delattre, J.-Y., 179 Franssen, E., 1155
Berkey, B., 1069 Chappell, R. J., 1025 DeLuca, A. M., 839 Freedman, G., 11, 105
Bernhard, E. J., 769 Chauvel, P., 237 Demard, F., 237 Friedman, C. P., 455
Bey, P., 935 Chen, H.-C., 541 Dempsey, J. F., 421 Friedman, W. A., 591
Biaglow, J., 833 Cheng, A., 213 Denekamp, J., 705 Fritsch, D. S., 455
Biaglow, J. E., 769, 871 Cheng, E. C., 11 Deppe, G., 1015 Fu, K. K., 1069
Biert, J., 623 Chevret, S., 21 DeVol, E. B., 91 Fukunaga-Johnson, N., 143
Biete, A., 191 Childress, C. H., 661 Dewhirst, M. W., 723, 855, 871 Fuss, M., 995
Bilsky, M., 391 Chotin, G., 21 Dillehay, L. E., 631 Fyles, A. W., 717, 751
1199
Gaballa, H. E., Hennequin, C., 21 Kelleher, D. K., 843, 861 Lichter, A. S., 1, 137, 651
Galakatos, A Heresbach, D., 29 Kessler, M. L., 651 Link, M. P., 125
Gallup, D. G., 79 Hicks, K. O., 641 Keus, R. B., 247 Littbrand, B., 705
Gamson, J., 795 Hilgers, F. J.M ., 247 Khafaga, Y., 601 Lloyd, D. K., 413
Garipagaoglu, M., 335 Hill, R. P., 717, 751 Khoo, V. S., 673 Lockett, M. A., 335, 1077
Gaspar, L. E., 263 Hill, S. A., 731 Kim, J. H., 789 Loeffler, J. S., 57 4
Gelblum, D. Y., 391 Hillmann, A., 1001 Kim, S., 795 Léfroth, P.-O., 305
Gerber, R. | Hinson, J., 269 Kim, S. H., 789 Lohr, F., 995
Gerweck, L. E Hiraoka, M., 785, 913 Kinashi, Y., 823 Longford, S., 391
Giannarelli, D Hirose, T., 351 Kinsella, T. J., 205 Loredo, L. N., 299
Gil, M., 977 Hirsch, A., 21 Kirkwood, J.. 269 Low, D. A., 213, 229, 681
Gilula, L., 125 Hoffman, J. P., 43, 105 Kirkwood, J. M., 581 Lunsford, L. D., 581
Giovinazzo, G Hofman, J., 1001 Klamut, H. J., 331 Luporsi, E., 935
Glicksman, A Homasson, J.-P., 21 Klein, E. E., 1163 Luse, R., 1063
Glickson, J. D Honess, D. J., 731 Knelles, D., 397 Luzi, S., 65
Glisson, B. S Hong, W. K., 479 Knéds, T., 1169 Lyons, M. K., 953
Goldberg, Z. | Hoogenhout, J., 623 Kobayashi, H., 1127
Goldstein, | Hoppe, R. T., 3 Koch, C. J., 641, 769, 833 Mac Manus, M. P., 365
Goldwein, J Horan, A. M., 833 Kocha, W. L, 319 Mackie, T. R., 205
Gomella, I Horenblas, S., 525 K6lbl, O., 397 MacLeod, C., 1033
Gonsalves, ¢ Hori, H., 799 Kolitsi, G., 551 Magdelenat, H., 179
Goodman, R Horsman, M. R., 701, 72 Komaki, R., 263, 469, 479 Mah, K., 1155
Goswitz, M R95 Kondziolka, D., 581
Manevich, Y., 769, 833, 871
Grado, G. I Hsi, R. A., 495 Kooy, H. M., 507
Mannel, R., 1015
Grado, M. M Huang. D.-D.. 1133 Kramer, C. A., 607 Manning, J., 125
Graham, M Huang, E.-Y., 541 Kriegshauser, J. S., 289 Manoux, D., 21
Graham, M. V Huang, G.-J., 929 Krishna, C. M., 839 Mantello, G., 65
Grasl, ( 803 Huang, W 37 Kristensen, I., 1169 Maolinbay, M., 437
Graus, F., 977 Hunjan, S., Kumar, S., 507 Marcial, V., 1069
Gray, A., 601 Hussey, D. H., 1049 Kupelian, P. A., 981
Marcus, K., 1113
Grecula, J., 1085 Kuwasaka, H., 799
Marcus, R. B., Jr., 147, 591
Greven, K. M Igrutinovic, L., 16] Kwa, S. L. S., 1 Marcy, P.-Y..,
Griffin, R. J Ikeda, H., 989 Kyprianou, K., 551 Maria, B. L..,
Griffin, T. W., 1063 Inagaki, J., 1127 Marks, L. B..,
Griffiths, L., 877 Inayama, S., 799 Ladekarl, M., 895 Marks, R. S., 969
Grigsby. P. W.. 335 Inomata, T., 799 Lagrange, J.-L., 237 Marsh, L. H., 137
Grimm, P. D., 1063 Ismail, M., 501 ahousen, M., 531 Martel, M. K., |
Grizzle, W. E., 817 Iwata, H., 1127 amproglou, I., 179 Martin, E. W., 545
Groves, E., 811 Iyer, R. V., 741 anciano, R., 43 Martin, R. F., 827
Gu, X.-Z., 929
anciano, R. M., 101 Martinez, A., 977
Guarneri, E. M., 1097 Jani, S., 1097 Lanzen, J. L., 723, 855 Martinez-Monge, R..,
Guillem, J., 325 Jee, K.-W., 437 Lapeyre, M., 935 Mason, K. A., 1137
GGuuiilllleemm,i n, J. FG.,. , 93551 JJeennkkiinn,s ., D.,W . 601T ., 871 LLaasrhs,o n,K . T.L .,R .,6 512 89 MMaasssounl,l o,R . V.P.,, 1704977
Gunderson Jensen, P. T., 1041 Launois, B., 29 Masunaga, S., 823
Guo, G. Z Jeremic, B., 161, 1091 Laurie, F., 125 Matrone, G. M., 651
Gwede, ( ji, M., 775 Lautenschlager, C., 35 Mattiucci, G. C., 65
Gynecology Tumor Group, the, 8 Joensuu, H., 373 Lawton, C., 469 Mauch, P. M., 1113
Johnson, D. J., Le, D., 747 Maxwell, R. J., 891
Hacke, W., 995 Jiirgens, H., 379, 1001 Lebesque, J. V., | Maylin, C., 21
Hackl, A., 531 Lee, C. G., 73 Mayo, M. S., 817
Hahn, E. W., 747 Kachur, A. V., 769 Lee, D.-J., 811 Mayo, W., 179
Hahn, S. M., 839 Kagami, Y., 989 Lee, H., 391 Mayr, N. A., 1049
Hall, E. J., 695 Kagan, A. R., 223 Lee, J. H., 143 McCollough, W. M., 147
Halle, J., 345 Kaiser, U. B., 573 Lee, J. S., 469, 479 McKenna, W. G., 769
Haller, D. G., 269 Kamuinsky-Forrett, M.-C., 935 Lee, W. R., 1069 McKeown, S. R., 763
Hanlon, A. L., 43, 105 Kanaan, I., 601 Leeper, D., 871 McNeil, E., 143
Hansgen, G., 35 Kancharla, S., 817 Lehnert, S. M., 413 McNutt, T. R., 205
Harms, D., 379 Kantor, G., 361 Leigh, B., 1055 McShan, D. L., 651
Harrison, L ; Kapp, D. S., 531 Leon, M. B., 1097 Meeks, S. L., 591
Hart, A. A. M., 2 Kapp, K. S., 531 Leone, M., 65 Melo, T., 737, 755
Harvey, E., 2"! Karlsson, E., 1147 Leopold, K. A., 1105 Mendenhall, N. P., 147
Hassounah, M., 60] Karnitz, L. M., 921 Lesiuk, H., 155 Mendenhall, W. M., 591
Haughey, B., 1077 Kasai, S., 799 Lessin, S., 361 Mercke, C., 1147
Hedley, D., 717 Katagiri, H., 1127 Leung, S. W., 541 Merlo, F. M., 717
Held, K., 833 Kavanagh, B. D., 1178 Lewis, P., 1055 Mermillod, B., 487
Hendriks, T., 623 Kavanagh, M.-C., 717 Li, A. E., 905 Meunier, B., 29
Henk, J. M., 807 Kedar, A., 147 Li, L., 899 Meyn, R. E., 185
1200
Micaily, B., 361 Okunieff, P., 885 Reddy, mh Pe SOP Shibata, T., 785, 913
Michalski, J. M., 213 Olsen, C. C., 817 Regine, W. F., 59 Shibui, S., 989
Michel, G., 487 Olt, G., 79 Reichel, M., 803 Shibuya, K., 785
Micheli, A., 1119 Ong, A. L., 855 Reid, J. M., 969 Shrieve, D. C., 573
Micke, O., 617 Ono, K., 823 Reinus, W., 125 Shulman, L. N., 1113
Mickle, J. P., 147, 591 Opeitum, A., 117 Reyes-Molyneux, N Shuster, J. J., 125
Milano, G., 237 Ortiz, H., 1069 Richardson, G. E., ‘ Siemann, D. W., 697, 899, 909
Milicic, B., 161, 1091 Oshodani, T., 799 Ritter, M. A., 205 Siewerdsen, J. H., 437
Milisavljevic, S., 161, 1091 Overgaard, J., 895 Roach, M., 263 Sigurdson, E. R., 43, 105
Millesi, W., 803 Oxman, T. E., 1105 Roach, M., Ill, 1055 Sim, B. G., 641, 905
Milosevic, M., 751 Oya, N., 785 Robbins, H. I., 1177 Simpson, J. R., 1077
Minsky, B. D., 51, 325 Robertson, P., 143 Sischy, B., 269
Mintz, G. S., 1097 Paliwal, B. R., 205 Rodriguez- Villalba, S., 1085 Skarlatos, J., 551
Mirabell, R., 487 Papadopoulou, M. V., 775 Roed, H., 1041 Skwarchuk, M. W., 169
Miranda, M., 191 Parliament, M. B., 263 Rojiani, A., 899 Slater, J. D., 299
Mirimanoff, R.-O., 487 Patchefsky, A., 105 Rook, A., 361 Slater, J. M., 299
Misra, V., 755 Patel, M. M., 1077 Rose, P. G., 1015 Smith, T. J., 269
Mitchell, J. B., 795, 839 Patrick, T. J., 421 Rosen, I. L., 661 Solin, L. J., 495
Mitsumori, M., 573 Patterson, L. H., 763 Rosendal, F., 1041 Song, C. W., 865
Miyamoto, C., 361 Paty, P. B., 325 Rosenman, J., 345 Sorosky, J. 1., 1049
Mohan, D. S., 981 Paty, P. P., 51 Rosenman, J. G., 455 Sotiropoulou-Lontou, A., 5
Mohan, R., 431 Paulussen, M., 379, 1001 Rossi, C. J., Jr., 299 Spahn, U., |
Monnier, P., 403 Pavelka, R., 803 Rostock, R., 811 Spector, G. J., 1077
Montana, G. S., 79 Pearlman, J., 257 Rotman, M., 1069 Spencer, S., 811
Moonen, L., 525 Peiffert, D., 935 Riibe, C., 379, 1001 Stackhouse, M. A., 817
Moore, D Perderau, B., 179 Rubin, P., 885 Steeves, R. A., 1177
Morales, A.., Perera, F. E., 117, Ruifrok, A. C. C., 1137 Steinvorth, S., 995
Moreno, V., Perez, C. A., 213, Russell, A. H., 263 Steuterman, S., 1097
Morgan, T. L., 223 Perret, M., 21 Russo, R. J., 1097 Stevens, C., 871
Morganti, A. G., 65 Peschke, P., 7 Ryan, L. M., 269 Stevens, G., 385
Mori, Y., 581 Petereit, D. G.., Sutt, L., 117, 277
Moro, D., 487 Petersen, R. O.., Sanchez-Reyes, A., 191 Stitt, L. W., 319
Morton, G., 1155 Pettaway, C Sandler, H., 437 Stobbe, C. C., 741
Mose, S., 959 Phan, J. L., 981 Sandler, H. M., 137, 143 Stodkilde-Jorgensen, H.,
Mott, L. A., 1105 Phillips, T. I Santini, J., 237 Storen, E., 1113
Motterlini, R., 849 Pickel, H., 531 Saracino, B., 1119 Stratford, I. J., 877
Movsas, B., 43 Pinilla, J., 87 Saran, F. H., 959 Stubbs, J. B., 421
Muhonen, T., 373 Pinola, C., 3 Sarkaria, J. N., 1025 StueckIschweiger, G. F.,
Mulholland, S. G., 501 Pintilie, M., 751 Sasai, K., 785, 913 Suchindran, S., 727
Munley, M. T., | Pisters, P. W. T., 563 Sauder, B., 257 Sugiura, H., 1127
Munn, R. K., 607 Pivot, X., 237 Sause, W. T., 469 Suh, J. H., 981
Murayama, S., 989 Plewes, E. A., 319 Saxer, A., 79 Sumi, M., 989
Mutch, D., 335 Poissonnet, G., 237 Scarpine, V Sun, L.-M., 541
Mutic, S., 229, 681 Pollack, A., 517, 563, 661, 1007 Schifer, | Suwinski, R., 943
Muzyczka, N., 909 Pollock, R. A., 563 Schatz, R. A., 1097 Suwinsky, R., 463
Mychalezak, B., 325 Poole, B. A., 849 Scheithauer, B. W., 351, 953 Suzuki, M., 823
Popma, J. J., 1097 Scher, R. M., 43 Swanson, G. P., 289
Nag, S., 545, 1085 Poschauko, J., 531 Schild, S. E., 351, 953 Swift, M., 1133
Nagasawa, H., 799 Powell, N. A., 731 Schmidt-Ullrich, K., 1178 Sylvester, J., 1063
Nagata, Y., 785 Prevost, B., 237 Schneider, M., 237
Nakayama, H., 989 Prisé, E. L., 29 Schneider, R. F., 741 Tables, L., 727
Narayana, A., 557 Prise, V. E., 849 Schomberg, P. J., 953, 969 Taghian, A., 464
Naudé, J., 803 Provins, S., 43 Schuck, A., 1001 ra, P., 277
Navickis, R. J., 289 Puisieux, F., 179 Schuller, D. E., 1085 Takagaki, M., 823
Neff, J., 125 Purdy, J. A., 1, 2 Schulte, R. W. M., 299 Takahashi, M., 1127
Nicolatou, O., 551 1163 Schultz, D. J., 495 Tanaka, M., 989
Nielsen, F. U., 891 Schutt, A. J., 269 Tapen, E. M., 1063
Nikolic, N., 161, 1091 Radany, E. H., 137 Scott, C., 469 Tarbell, N. J., 1113
Nilsson, P., 1169 Radwan, J. S., 313 Scott, C. B., 263 Taylor, J.M . G., 943
Nishioka, A., 799 Ragde, H., 1063 Seaward, S. A., 1055 Taylor, M., 319
Nisi, K., 953 Rainer Bowie, C. A., 365 Seifert, W. F., 623 Teichman, S. L., 299
Noda, M., 913 Rajkumar, S. V., 969 Sessions, D., 1077 Teirstein, P. S., 1097
Nomura, K., 989 Raleigh, J. A., 727 Shabanah, M. Al., 601 Teissier, E., 22 37
Nyandoto, P., 373 Raleigh, S. M., 763 Sham, E., 711 Tempany, C. M., 507
Ralston, A., 385 Sharpe, G., 959 Ten Haken, R. K.., 1,
Oetzel, D., | Raoul, J.-L., 29 Shastri, V. R., 631 Teschendorf, C., 909
Ogawa, Y., 799 Raunecker, F., 397 Shaw, E. G., 953 Tetteh Ago, C., 313
Okajima, K., 865 Rauth, A. M., 331, 737, Shibamoto, Y., 161, 1091 Thames, H. D., 1137
Theuws, J Venkatesan, V. M., 313 Weidner, G. J., 1049 Wong, W. W., 351, 953
Thews, O 3 Verger, E., 977 Weigel, C., 35 Woodtli, A., 403
Thilmann, C., 95° Verhofstad, A. A. J., 623 Weil, M., 1137 Wroblewski, K., 871
Thomadsen, B u Videtic, G. M. M., 319 Weinberg, V.. 55 Wu, Q., 431
Thomas, G. M.. 7 Vikram, B., 1069 Weiner, L. M.. 43
Thompson, E., 12 Villa, S., 977 Weissberg, J. B 33 amamura, S., 1127
Thyss, A., 23 Vincent, M. D., 319 Wenz, F., 995 ang, C.-W., 541
Tinger, A 3 Vifiolas, N., 977 West, C., 1147 app, D. T. T., 413
Tokuuye, K., 98' Vlachaki, M. 1 Westfall, | 3 aya, R., 977
Topulos, G ] Voet, H. V. D., 525 White, C., 3 Yin, W.-B., 929
Tormey, D. ¢ 69 olkman, S. K., 651 Widder, J 3 Yonemoto, L. T., 299
Torrey, M., 12 von Roemeling, R.., Widmark, A., 305 Yorkston, J., 437
ozer, G. M i mnderheid, | ; Wiegand-Packard, L., 1105 Yoshida, S., 799
ravis, E. I \¢ roman, B. T Wildermuth, S., 995 Yu, E., 277
Tredaniel, J., 21 Wilkes, M. M., 289 Yuan, X., 631
Tripuranen 10% ‘ 5 Williams, J. A., 421, 631
Trotti, A., 257, 81 agniere Williams, J. R., 631 Zagars, G. K., 517, 563, 661,
Tuttle, S., 833 aites 705 Williams, R., 1163 1007
Tuttle, S. W., 76¢ ] alch | Williamson, J. F., 421 Zaidi, S. T., 611
allner Willich, N., 617, 1001 Zhang, D.-W., 929
alton 7 Wilson, J., 849 Zhang, R.-G., 929
5 Wilson, P., 959 Zhang, X., 737
Wilson, W. R., 641, 905 Zhang, Z.-X., 929
‘ Wink, D. A., 795 Zhen, W., 1049
an der Voet $7 annenmacher Winkelmann, W., 37 Zhou, S.-M., 73
Van Dyk, J., 2 anogho Winquist, E. W., 313 Zhu, J., 413
Varia, M. A., 727, 1015 ardman Withers, H. R., " 3 3 Zhu, R., 213
Vaughan, A arrington Wobbes, T., 623 Zoubek, A., 379
Vaupel 43, 86 ebb, S., 67 Wong, P. S., 747 Zwicker, R. D., 431
Int. J. Radiation Oncology Biol Phys., Vol. 41, No. 5, pp. 1203-1205, 1998
Copyright © 1998 Elsevier Science Inc
Printed in the USA. All rights reserved
PII S0360-3016(98)00000-0
SUBJECT INDEX
Breast preservation, 345 CYP 2D, 763 Fractionated radiotherapy, 905
BSH, 823 CYP 3A, 763 Fractionation, 247, 705
Cysteine, 833 Free radicals, 839
AAV, 909
Cytokines, 169
Accelerated hyperfractionation,
803 G
D
Active matrix flat-panel imager,
437 "3H, 169
Acute myelogenous leukemia, °3H mouse mammary carcinoma, Gene therapy, 755, 817
1113 895 Depression, 1105 Gleason score, 1055
ADEPT, 917 ‘amptothecin, 785 Desmoid tumor, 1007 Glioblastoma, 969
adjuvant radiation, 101 “ancer, 1105 Detective quantum efficiency, 437 Glioblastoma multiforme, 981
Adjuvant therapy, 51 ‘ancer of the esophagus, 2 Diagnostic, 737 Glioma, 421
Advanced uterine cancer, 1041 “arbogen, 855 digital portal images, 455 Glutathione, 185, 769, 833
Advanced vulvar cancer, 79 “arbogen breathing, 865 DMXAA, 905 GM-CSF, 551
Adverse effects, 373 “arbon monoxide, 849 Dose escalation, 137 Granulocyte—colony-stimulating
aFGF, 885 “arcinogenesis, 385 Dose modification, 413 factor (G-CSF), 1113
Age, 977 ‘ardiac adenocarcinoma, 929 Dose-escalation, 305 GSH, 191
Dose—volume histogram, 1, 65,
Age at presentation, 959 ‘ardiac effect, 11
Anal canal carcinoma, 331 ‘ell kinetics, 711 507 H
Anaplastic astrocytoma, 969 Cellular respiration rate, 843 Dose-response, 943
Anemia, 1069 Cervical cancer, 541, 1025, 1049 Dosimetry, 385, 421
Anesthesia risk, 1049 Cervical carcinoma, 531, 1015 downstaging, 43, 935 Haemoxygenase, 849
Angiogenesis, 877 Cervix carcinoma, 751 DT-diaphorase, 331 Hamster, 403
Animal model, 617 Cervix-neoplasm, 91 HDR brachytherapy, 541, 1025
Antimetastasis, 799 Chemoradiation, 79, 1015 Head neck carcinoma, 811, 1069
Antioxidants, 191 Chemotherapeutic agents, 775 Head neck neoplasms-radiother-
Antivascular agent, 905 Chemotherapy, 29, 365, 373, 379, apy, 257
Anxiety, 1105 479, 487, 969, 1091, 1127 Early glottic cancer, 247 Head neck tumors, 35, 1085
Apoptosis, 185 Chemotherapy introduction, 953 Economic analysis, 87 Heart volume, |!
AQS4N, 763 Chest wall recurrence, 495 EFS, 641 Hemoglobin, 35
Arteriovenous malformation Childhood cancer, 379 EGF, 1137 Heterotopic ossification, 397
(AVM), 995 Childhood leukemia, 385 EGF-R, 1137 Heterozygotes, 1133
Artery radiation effects, 617 Cisplatin, 79, 413, 479, 969, 1015 Elderly patients, 981 Hexafluorobenzene, 747
Ataxia-telangiectasia, 1133 clinical presentation, 91 Electron beam, 1085 High dose rate, 325
Attention, 995 Clinical radiotherapy, 705 Electronic portal imager, 437 High precision conformal radio-
Automated treatment delivery, 651 Clinical results, 573 Electroporation, 823 therapy (HPCRT), 305
Azomycin nucleoside, 741 Colorectal adenocarcinoma, 545 Endobronchial brachytherapy, 21 High risk, 1055
Combined modality, 487 Endometrial cancer, 101, 1033, High-dose-rate, 1033
Combined treatment, 29, 929 1049 High-dose-rate brachytherapy, 531
Combined-modality therapy, 1077 Endometrial neoplasms, 87 HL-91, 737
Combretastatin, 891, 899 Enzyme-prodrug therapy, 917 Hodgkin's disease, 373
Combretastatin A-4 disodium Ependymoma, 953 Human glioma, 631
B.i.d. radiotherapy, 2 249/ phosphate, 895 Eppendorf histograph, 895 Human squamous cell carcinoma,
B6, 169 Complications, 247, 391, 1025 Errors, 651 921
Bcl-2 oncogene, 185 Compression, 607 Erythropoietin, 913 Human tumor cell lines, 1147
BCNU, 969 Computer control, 651 Esophageal carcinoma, 2 Human tumors, | 147
bFGF, 885 Computer simulation, 705 Etanidazole, 1069 Hydrogen peroxide, 769
Biodegradable polymer, 413, 631 Computer-assisted radiotherapy, Etoposide, 969 Hyperfractionated radiation ther-
Biological response modifier, 799 591 Ewing’s sarcoma, 125, 379, 1001 apy, 479
Bioreduction, 755, 763 Computer-assisted radiotherapy Extended field radiation, 1015 Hyperfractionation, 470
Bioreductive drugs, 641, 775, 909 planning, 591 Extravascular diffusion, 641 Hypopharynx carcinoma, 237
Bladder cancer, 525 Concurrent, 479 Hypotension, 839
”™BnAO, 737 Concurrent Chemoradiation, 470 Hypoxia, 35, 641, 705, 711, 723,
Bone metastases, 1119 Conformal radiotherapy, 673 737, 747, 751, 755, 763, 795,
bone metastasis, 161 Conformal therapy, 651, 1169 843, 913
Brachytherapy, 87, 101, 289, 545, Conformity index, 1169 '°F NMR, 747 Hypoxia marker, 727
1033, 1041, 1049, 1063 Conservation therapy, 335 Failure patterns, 470 Hypoxia-inducible factor 1, 913
Brain metastases, 155 Conservative surgery, 105 Field localization errors, 223 Hypoxia-reoxygenation, 723
Brain metastasis, 581 Contrast-detail study, 437 5-Fluorouracil, 79, 319, 1015 Hypoxia-responsive element, 913
Brain neoplasm, 421 Cord, 607 Flavin adenine dinucleotide, 871 Hypoxic cell radiosensitizer, 799
Brain neoplasms, 591 CPT-11, 785 Flow redistribution, 861 Hypoxic cell sensitizer, 1069
Brain tumors, 137, 969 Craniopharyngioma, 601 Fluorescence, 871 Hypoxic cytotoxin, 811]
Breast, 11 CYP 1A, 763 Follicular, 365 Hypoxic marker, 741
Breast cancer, 105, 117, 495 CYP 2C, 763 Fractionated radiation, 413 hypoxic-specific factor, 741
1203
Lung volume, | Prophylactic cranial irradiation,
Lymphoma, 185, 365 3R5
Prospective studies, 257
1, 421 O, availability, 843 Prostate, 299, 1063
IFN, 885 observer studies, 455 Prostate cancer, 73, 2
IGF, 885 Oral f toposide 507
image analysis, 455 Oral mucositis, Prostate carcinoma,
Implant, 507 Magnetic resonance imaging Organ motion, 213 Prostate motion, 661,
Indole-3-acetic J RO] Organ preservation, 51 Prostate phantom, 205
Inoperable endometr Magnetic resonance spectroscopy Oropharynx carcinoma, 5237 Prostate radiotherapy, 661
1025 R9] Osmotic cervical dilation, 1049 Prostate-specific antigen, 289,
Inoperable lung in Malignant fibrous histiocytoma Osmotic pumps, 413 1055
Intensity modulated radi S63 Oxidation therapy, 917 Proton, 299
ipy y Malignant glioma, 97 Oxidative stress, 191 PSA, 299
Intensity modulatior Malignant melanoma, 581 Oxygen, 855 Psycho-oncology, 1105
Intensity-modulated Malignant peripheral nerve sheath Oxygen consumption, 87] Pulmonary embolism, 1063
apy, 681 tumor, 351 Oxygen tension, 747 Pulsed dose rate, 1041
Interferon, ¢ Mean dose Oxygenation strategies, 843
Interstitial photodyr Mechanism, 755
43 Medulloblastoma, 143 Q
Intestine, 169 MEK Erk protein kinases, 921
Intimal hypIe rp| Memory, 995
Intracavitary brac Meta-iodobenzyl guanidine Quality assurance, 2
iracavitar tf (MIBG). 871 651, 1163
Metallothionein _ Quality of life,
Intraoperative rac Methylene blue, 769 pain relief, 161, 1119 Questionnaires, 2
295 Methylxanthine derivatives, 861
Palladium, 289
Intratumora cl Microcire ulation, 843 Palladium-103, 1063
Intrinsic radioset Microvascular O content, 843 Palliative radiotherapy, 1119
lodine 289. 54j5 Mild hyperthermia, 865 Para-aortic node metastases, 1015
llooddiondee-o1x25 ,y uri1d0 63 MMoidtuolmayticoinn Co,f O3,3 1, su8p0p3l y, 843 PPaartahoorltoigcy , rec3u5r1 rence, 545 RRa&bVb,i ts, 116631 7
Ipsilate ral breast Morbidity, 391, 1025 Patterns of failure, 263 Race, 517
IlrsroaedfIifOaestc itoinv e mMMooorrutbsaieldi ittyyj ejumnourmt,al ity|, 1379 1 PPeelnvtiocx ifryelcluirnree,n ce8,6 1 545 Radi6a0t7i,o n,6 111,0 5,6 17,16 9,7 851,8 5,7 892,5 7,7 95
Peroxidases, 917 Radiation complications, 11]
MPNST, 351
Multicellular layers, 641 pH, 871 Radiation dose, 501
Multidisciplinary therapy Pharmacokinetic survey, 237 Radiation injury, 989
Multivariate analysis, 21 Phosphotyrosyl proteins, 833 Radiation pneumonitis, |
Photon dose-calculation algorithm Radiation response, 865, 921,
Murine, 839
verification, 681 113
Photosensitizer, 403 radiation therapy, 91, 223, 263,
Pimonidazole, 727 277, 345, 385, 495, 501, 507,
Pituitary adenoma, 573 oh7, 224. 581, 817, 953, 969,
Planning target volume, 661, 673 1007, 1055, 1091, 1127, 1133,
N-acetyl-cysteine, 833 Platelet-derived endothelial cell 1163, 1169
Laryngeal cancer, 557 NAD(P)H, 871 growth factor, 877 Radiation therapy planning, 65
Larynx preservation NADPH, 769 P-NMR in vivo, 871 radiation/chemotherapy, 43
Late effects, 21, 1041 Neurofibrosarcoma, 35 pO,, 865 radical hysterectomy, 91
L-buthionine-SR-sulfoximine, 8 3 Neurogenic sarcoma, 35] POG, 125 Radical prostatectomy, 501
LDF, 885 Neurological status, 1127 Polarographic pO, measurements, Radioactive fluid, 421
Learning Neuropsychology, 995 35 Radiobiology, 191
Leukemia, 379 New radiotherapy technique, 305 Polymerase chain reaction, 331 Radiochemotherapy, 237, 1001
Lidocaine, 54] 9L Glioma tumor, 871 Port films, 223 Radioprotection, 839
Light delivery, 403 Nitric oxide, 795, 849 Postmenopausal, 117 Radioresistance, 705
LINAC, 573 Nitroxide, 839 Postoperative irradiation, 1077 Radiosensitivity, 1133, 1147
Liposarcoma 563 Nitroxyl, 795 Potentiation, 775 Radiosensitization, 611, 631, 817
Local control, 1001 NLCQ-1, 775 ppS59fyn kinase, 833 Radiosurgery, 581, 995
Local electron beam irradiation Non-small cell lung cancer, 479 Preoperative irradiation, 1077 Radiotherapy, 29, 73, 125, 143,
6) 487 Preoperative radiation therapy, 147, 155, , 247, 299, 313,
Locally advanced breast cancer Nonsmall-cell lung cancer, 263, 39 319, 365, 373, 379, 421, 479,
345 109! Preoperative radiotherapy, 929, 487, 525, 551, 557, 563, 711,
Local-regional recurrence, | Nonsteroidal anti-inflammatory 935, 943 789, 959, , 981, 1085,
Locoregional control, 247 drugs, 397 pre-operative therapy, 43 1105, 1155
Locoregional recurrence, 335 Normal tissue complication proba Prodrugs, 755 Rat, 179
Low-dose rate irradiation, | 147 bility, | Prognosis, 517, 1007 Rats, 723
Low-grade, 365 Normal tissue tolerance, 989 prognostic factors, 91, 155, 299, Reactive oxygen species, 833
Lung, |! NQO1, 909 531, 935, 959, 1001 Record verify, 651, 1163
Rectal cancer, 43, 51, Spinal metastasis, 1127 Three-dimensional conformal radi Tumour blood flow, 849
935. 943 Spontaneous murine tumors, 895 ation therapy, 65 Tumour vasculature, 891
recurrence rate, 91 squamous cancer, 91 Three-dimensional conformal ra- Tumourigenicity, 877
Recurrences, 1085 Squamous cell carcinoma, 403 diotherapy, 72 73 TX-1877, 799
Recurrent gynecologic cancer, SR 4233, 811 Three-dimensional treatment plan
1041 Staging, 91 ning, 137, 431
Recursive partitioning analysis Stereotactic radiosurgery, 391, Thymidine phosphorylase, 877
263 431, 591 Thymidylate Synthase Inhibitor,
RReeldaopxs e,s ca3n6n5i ng, 871 Stere9o8t9a ctic radiotherapy, 573, Thyr7o8i9d , 385 Uncertainty, 213
Relapse analysis, 1001 Stereotaxic techniques, 591 Tirapazamine, 641, 811, 905 Unilesional mycosis fungoides
Reoxygenation, 751 Strain, 169 361
Restenosis, 617 Striated muscle, 403 TTiLsDs,u e 3d8a5 mage, 403 Unresectable non-small cell lung
Retinoic acid, 611 Subclinical disease, 943 cancer, 470
RIF-1 mouse tumor model, 413 Supportive care, 23 27 INF, 885
TNF-alpha, 169
Surgery, 125, 147, 155, 929, 953,
Tomotherapy, 229, 681
977, 981
Tonsil, 107
surgical treatment, 91
Tonsillar fossa, 10
Survival, 470, 1127 Vascular endothelial growth fac-
Topical anesthesia, 541
survival outcome, 91 Topoisomerase I, 785 tor, 913
Saudi, 91 Synovial sarcoma, 563 Vascular injuries, 617
Total body irradiation, 179, 1113
Scale development, 257 Vascular targeting, 899
Total hip replacement, 397
SCCVII tumor cells, 823 Virally directed enzyme/prodrug
Toxicity, 470
Second cancer, 373 therapy, 909
Second neoplasms, 379 Treatment margin, 673 Vulvar cancer, 335
Second primary tumor, 557 Tamoxifen, 117 Treatment planning, 7
Segmental intensity modulation, Target position variability, 1155 treatment results, 91
651 Target-volume definition, 277 rreatment time, 525
Seminoma, 313 Technetium chelate, 741 Treatment verification, 681
Sensitizer, 795 TGFB, 885, 1137 Tumor, 747
Single fraction radiation therapy, TGF-beta, 169 Tumor blood flow, 855 Whole-body dose,
161 Thalassemia, 607 Tumor growth delay, 905 Workstation, 455
Single-chain antibody, 817 3D Conformal, 213 Tumor hypoxia, 727, 895
Smooth muscle cells, 617 3-D Conformal radiotherapy, 205 Tumor necrosis, 895
SN-38, 785 3D image registration, 661 Tumor oxygenation, 35, 843, 861
SOD, 179 Three-dimensional, 1169 Tumor perfusion, 861
Solid tumours, 737 Three-dimensional (3D) treatment Tumor proliferation, 525, 943 Xenografts, 711
Spinal, 607 planning, 277 Tumors, 797323 X-ray, 617